Juvion Health Sciences

What Juvion Health Sciences does

Juvion Health Sciences is an early-stage Swiss biotech startup headquartered at the EPFL Innovation Park in Lausanne, founded and led by CEO Dr. Soumya Banerjee, with Prof. Brian D. McCabe (Director of the EPFL Brain Mind Institute) chairing its Scientific Advisory Board. The company targets the biology of age-related motor decline, developing next-generation therapeutics aimed at preserving neuron-muscle communication and motor ability in older adults. Its scientific premise is that deterioration of motor terminals connecting spinal neurons to muscles is an under-addressed driver of sarcopenia, neuropathy, and immobility in the over-60 population, a segment Juvion cites as one-third suffering significant mobility issues.

At the core of Juvion's offering is a proprietary screening technology platform that combines robotics, machine vision, and AI analysis to quantitatively assess motor ability in vivo during aging, using Drosophila and rodent models. This platform is used to identify and validate naturally-derived compounds that preserve neuron-muscle communication, and it underpins both the company's Motor Aging Diagnostics capability and its therapeutics pipeline. The lead asset, Juvion-001, is a plant-derived supplement shown in multiple assays to increase motor ability during middle and old age and to delay age-dependent motor decline in animal models; new preclinical data were announced in June 2025. The company states its foundational research has been published in top-tier science journals and that its technology is patent pending. Future product candidates beyond Juvion-001 form a broader Motor Aging Therapeutics pipeline, with potential licensing of underlying therapeutic candidates for age-related motor decline at a later stage.

Juvion's business model is currently pre-commercial. Juvion-001 is positioned as a science-supported supplement expected to become available in select markets in 2026, implying a future consumer/supplement unit-sales revenue stream with possible later licensing of therapeutic candidates. There is no publicly disclosed pricing, no enterprise or B2B customers, and the only disclosed capital event to date is a 100,000 CHF (approximately USD 110,000) tech seed loan from the FIT Foundation in January 2025. Non-dilutive momentum has been built through selection into multiple private accelerator programs, including GENILEM (3-year program), IMD's 2025 Startup Competition (winner), MassChallenge 2025 (top 8% of global applicants), the dhc/Tenity Digital Health Accelerator, and Swiss Venture Lab's Venture Leader Biotech, with the founder also conducting a Boston-based investor and business development roadshow in mid-2025. The company maintains an India-based Medical Affairs and Business Commercialization function, signaling early intent to address international markets beyond Switzerland.

Name

Juvion Health Sciences

Legal name

Juvion Health Sciences

Website

https://juvionls.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Juvion Health Sciences is a Lausanne-based early-stage biotech developing next-generation therapeutics to preserve neuron-muscle communication and motor ability during aging, using a proprietary robotics, machine vision, and AI screening platform. Its lead candidate, the plant-derived supplement Juvion-001, is targeted for 2026 launch in select markets.

Ownership category

akta.pro rank

Product category

Aging Therapeutics / Longevity Supplements

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Healthy Aging & Longevity Lifestyle Coaching (HSADAGAK)

Keywords

• Aging therapeutics
• Motor health supplements
• Neuron-muscle therapeutics
• Biotech screening platform
• Healthspan longevity

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Future consumer/therapeutic product sales (Juvion-001): Juvion-001 is positioned as a plant-derived supplement expected to become available in select markets in 2026. The company is currently pre-commercial; revenue model implies unit sales of a science-supported supplement for motor health during aging, with potential licensing of underlying therapeutic candidates for age-related motor decline at a later stage.

Go-to-market motion1 record

Core offering

Juvion Health Sciences develops next-generation, plant-derived therapeutics designed to preserve neuron-muscle communication and motor ability during aging, identified through a proprietary screening platform that combines robotics, machine vision and AI analysis. Its lead product candidate Juvion-001 is a plant-derived supplement shown to increase motor ability during middle and old age and is expected to become available in select markets in 2026.

Product overview

Juvion Health Sciences offers a single unified proprietary screening platform — the Motor Aging Platform — that combines robotics, machine vision and AI analysis to quantitatively assess motor ability in vivo during aging. This platform powers both its diagnostics capability (Motor Aging Diagnostics) and its therapeutics pipeline (Motor Aging Therapeutics), whose lead asset, Juvion-001, is a plant-derived supplement expected to launch in select markets in 2026 to promote motor health during aging.

Differentiator

Problem solved

Functional benefit

Brands

• Juvion-001: Plant-derived supplement and lead product candidate designed to increase motor ability during middle and old age; expected to become available in select markets in 2026.

Products and services

• Juvion-001 Juvion's first product candidate: a plant-derived, science-supported supplement designed to increase motor ability during middle and old age, validated in multiple assays of motor function during aging. Targeted at adults seeking to preserve mobility and healthspan; expected to become available in select markets in 2026.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Elysium Health: Elysium commercializes science-backed longevity supplements (e.g., Basis/NR, Signal) with a similar go-to-market model — taking aging biology out of the lab and into consumer supplements — making it a directly comparable commercial peer for Juvion-001.
• BioAge Labs: BioAge is a clinical-stage biotech developing therapeutics that target the molecular drivers of aging, with a pipeline including programs on muscle and motor aging — directly comparable as an aging-therapeutics peer operating in the same longevity/biotech category.
• Loyal for Dogs: Loyal is developing therapeutics to extend dog healthspan, with a primary focus on mobility and motor function in aging — the same biological axis (motor aging, mobility preservation) that Juvion targets, making it the closest conceptual peer despite operating in companion animal health.

Emerging players

• NewLimit: NewLimit is an early-stage biotech developing epigenetic reprogramming therapies to treat age-related disease — an emerging player in aging therapeutics with comparable stage and a programmatic drug-discovery approach, though with a different core mechanism.
• Retro Biosciences: Retro Biosciences is a Sam Altman-backed early-stage longevity biotech pursuing cellular reprogramming, autophagy, and plasma-related therapies — an emerging peer in the aging-therapeutics space with comparable company-stage and mission.
• InsideTracker: InsideTracker offers personalized healthspan and longevity diagnostics and interventions — a comparable emerging player that mirrors Juvion's diagnostic-plus-therapeutic approach to aging, with a more developed consumer/commercial footprint.
• Tally Health: Tally Health is a consumer longevity company offering epigenetic age testing and science-backed interventions — an emerging peer that combines aging diagnostics and consumer-facing therapeutics, paralleling Juvion's planned Motor Aging Diagnostics + Juvion-001 dual offering.

Broad incumbents

• Altos Labs: Altos Labs is a well-capitalized biotech pursuing cellular rejuvenation programming to restore cell health and reverse disease — a broad incumbent in the longevity therapeutics category with overlapping aging-biology focus, though targeting different mechanisms.
• Calico Life Sciences: Calico (Alphabet-backed) pursues fundamental biology of aging and age-related diseases with a long-horizon research and therapeutic pipeline — a broad incumbent in aging biology with overlapping scientific territory (motor/neuromuscular aging) but vastly greater resources.
• Insilico Medicine: Insilico is an AI-driven drug discovery company focused on aging and age-related diseases, combining machine learning with traditional pharma development — relevant as a broader incumbent in AI-enabled aging therapeutics, though operating at substantially larger scale and capital.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/juvion-health-sciences

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Juvion Health Sciences